Current Neurology and Neuroscience Reports

, Volume 2, Issue 6, pp 527–533

Critical illness myopathy and polyneuropathy

  • Shawn J. Bird
  • Mark M. Rich


Neuromuscular weakness commonly develops in the setting of critical illness. This weakness delays recovery and often causes prolonged ventilator dependence. An axonal sensory-motor polyneuropathy, critical illness polyneuropathy (CIP), is seen in up to one third of critically ill patients with the systemic inflammatory response syndrome (usually due to sepsis). An acute myopathy, critical illness myopathy (CIM), frequently develops in a similar setting, often in association with the use of corticosteroids and/or nondepolarizing neuromuscular blocking agents. These patients are often difficult to evaluate due to the limitations imposed by the critical care setting and may be further complicated by the presence of both CIP and CIM in varying degrees. This paper reviews the clinical and electrophysiologic features of these disorders, as well as the putative pathophysiology. In the case of CIM, an animal model has provided evidence that weakness in this disorder is caused by muscle membrane inexcitability due to altered membrane sodium currents and loss of myosin thick filaments.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Lacomis D, Petrella JT, Giuliani MJ: Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve 1998, 21:610–617.PubMedCrossRefGoogle Scholar
  2. 2.
    Rich MM, Bird SJ, Raps EC, et al.: Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997, 20:665–673.PubMedCrossRefGoogle Scholar
  3. 3.
    Trojaborg W, Weimer LH, Hayes AP: Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy —a reappraisal. Clin Neurophysiol 2001, 112:1586–1593. A detailed electrophysiologic study in patients with critical illness myopathy utilizing direct muscle stimulation, quantitative electromyography, and motor unit estimation.PubMedCrossRefGoogle Scholar
  4. 4.
    Lacomis D, Zochodne DW, Bird SJ: Critical illness myopathy. Muscle Nerve 2000, 23:1785–1788. A review article that suggests diagnostic criteria for critical illness myopathy.PubMedCrossRefGoogle Scholar
  5. 5.
    David WS, Roehr CL, Leatherman JW: EMG findings in acute myopathy with status asthmaticus, steroids and paralytics: clinical and electrophysiologic correlation. Electromyogr Clin Neurophysiol 1998, 38:371–376.PubMedGoogle Scholar
  6. 6.
    Campellone JV, Lacomis D, Kramer DJ, et al.: Acute myopathy after liver transplantation. Neurology 1998, 50:46–53.PubMedGoogle Scholar
  7. 7.
    Hanson P, Dive A, Brucher JM, et al.: Acute corticosteroid myopathy in intensive care patients. Muscle Nerve 1997, 20:1371–1380.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirano M, Ott BR, Raps EC, et al.: Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992, 42:2082–2087.PubMedGoogle Scholar
  9. 9.
    Hoke A, Rewcastle NB, Zochodne DW: Acute quadriplegic myopathy unrelated to steroids or paralyzing agents: quantitative EMG studies. Can J Neurol Sci 1999, 26:325–329.PubMedGoogle Scholar
  10. 10.
    Berg DK, Hall ZW: Increased extrajunctional acetylcholine sensitivity produced by chronic post-synaptic neuromuscular blockade. J Physiol 1975, 244:659–676.PubMedGoogle Scholar
  11. 11.
    Op de Coul AA, Lambregts PC, Koeman J, et al.: Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation. Clin Neurol Neurosurg 1985, 87:17–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Rich MM, Teener JW, Raps EC, et al.: Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996, 46:731–736.PubMedGoogle Scholar
  13. 13.
    Zochodne DW, Ramsay DA, Saly V, et al.: Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994, 17:285–292.PubMedCrossRefGoogle Scholar
  14. 14.
    Bird SJ: Critical care: myopathies and disorders of neuromuscular transmission. In Neuromuscular Function and Disease. Edited by Brown WF, Bolton CF, Aminoff MJ. Philadelphia: Harcourt-Brace; 2002:1507–1520.Google Scholar
  15. 15.
    Road J, Mackie G, Jiang T, et al.: Reversible paralysis with status asthmaticus, steroids, and pancuronium: clinical electrophysiological correlates. Muscle Nerve 1997, 20:1587–1590.PubMedCrossRefGoogle Scholar
  16. 16.
    Ashcroft FM: Ion Channels and Disease. London: Academic Press; 2000.Google Scholar
  17. 17.
    Rouleau G, Karpati G, Carpenter S, et al.: Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 1987, 10:428–438.PubMedCrossRefGoogle Scholar
  18. 18.
    Massa R, Carpenter S, Holland P, Karpati G: Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992, 15:1290–1298.PubMedCrossRefGoogle Scholar
  19. 19.
    Rich MM, Pinter MJ, Kraner SD, Barchi RL: Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1998, 43:171–179.PubMedCrossRefGoogle Scholar
  20. 20.
    Rich MM, Pinter MJ: Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001, 50:26–33. A patch clamp analysis of sodium current in an animal model of critical illness myopathy demonstrating that an altered voltage dependence of sodium channel inactivation may underlie electrical inexcitability of muscle in this syndrome.PubMedCrossRefGoogle Scholar
  21. 21.
    Pappone PA: Voltage-clamp experiments in normal and denervated mammalian skeletal muscle fibres. J Physiol 1980, 306:377–410.PubMedGoogle Scholar
  22. 22.
    Rich MM, Kraner SD, Barchi RL: Altered gene expression in steroid-treated denervated muscle. Neurobiol Dis 1999, 6:515–522.PubMedCrossRefGoogle Scholar
  23. 23.
    Ji S, Sun W: Voltage-dependent regulation of modal gating in the rat SkM1 sodium channel expressed in Xenopus oocytes. J Gen Physiol 1994, 104:625–643.PubMedCrossRefGoogle Scholar
  24. 24.
    Bendahhou S, Cummins TR: Serine-1321-independent regulation of the mu 1 adult skeletal muscle Na+ channel by protein kinase C. Proc Natl Acad Sci 1995, 92:12003–12007.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang Y, Hartmann HA: Glycosylation influences voltagedependent gating of cardiac and skeletal muscle sodium channels. J Membr Biol 1999, 171:195–207.PubMedCrossRefGoogle Scholar
  26. 26.
    Larsson L, Li X, Edstrom LI, et al.: Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000, 28:34–45. A study examining protein and mRNA levels of muscle structural proteins in muscle biopsies from patients with critical illness myopathy.PubMedCrossRefGoogle Scholar
  27. 27.
    Showalter CJ, Engel AG: Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997, 20:316–322.PubMedCrossRefGoogle Scholar
  28. 28.
    Rich MM, McGarvey ML: ECG changes during septic shock. Cardiology 2002, in press.Google Scholar
  29. 29.
    Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ: Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984, 47:1223–1231.PubMedGoogle Scholar
  30. 30.
    Bolton CF, Laverty DA, Brown JD, et al.: Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1986, 49:563–573.PubMedCrossRefGoogle Scholar
  31. 31.
    Zochodne DW, Bolton CF, Wells GA, et al.: Critical illness polyneuropathy. Brain 1987, 110:819–842.PubMedCrossRefGoogle Scholar
  32. 32.
    Zifko U, Zipko H, Bolton CF: Clinical and electrophysiological findings in critical illness polyneuropathy. J Neurol Sci 1998, 159:186–198.PubMedCrossRefGoogle Scholar
  33. 33.
    Witt NJ, Zochodne DW, Bolton CF, et al.: Peripheral nerve function in sepsis and multiple organ failure. Chest 1991, 99:176–184.PubMedGoogle Scholar
  34. 34.
    Berek K, Margreiter J, Willeit J: Polyneuropathies in critically ill patients: a prospective evaluation. Intensive Care Med 1993, 22:849–855.Google Scholar
  35. 35.
    Leijten FS, Harinck-DeWeerd JE, Poortvliet DC, De Weerd AW: Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996, 22:856–861.PubMedGoogle Scholar
  36. 36.
    DeLetter MC, Schmitz PI, Visser LH, et al.: Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001, 29:2281–2286. This study prospectively evaluated risk factors for the development of critical illness polyneuropathy or critical illness myopathy. They found that a high-risk group could be identified by the presence of systemic inflammatory response syndrome and more severe critical illness, as measured by the Acute Physiology and Chronic Health Evaluation (APACHE)-III score.CrossRefGoogle Scholar
  37. 37.
    Bolton CF: Electrophysiologic studies of critically ill patients. Muscle Nerve 1987, 10:129–135.PubMedCrossRefGoogle Scholar
  38. 38.
    Hund E, Genzwurker H, Bohrer H, et al.: Predominant involvement of motor fibres in patients with critical illness polyneuropathy. Br J Anaesth 1997, 78:274–278.PubMedGoogle Scholar
  39. 39.
    Teener JW, Rich MM, Bird SJ: Other causes of acute weakness in the intensive care unit.In Critical Care Neurology. Edited by Miller DH, Raps EC. Boston: Butterworth-Heinemann; 1999:69–89.Google Scholar
  40. 40.
    Bolton CF: Clinical neurophysiology of the respiratory system. Muscle Nerve 1993, 16:809–818.PubMedCrossRefGoogle Scholar
  41. 41.
    Zochodne DW, Bolton CF, Gilbert JJ: Polyneuropathy in critical illness: pathologic features. Ann Neurol 1985, 18:160–166.Google Scholar
  42. 42.
    Druschky A, Herkert M, Radespiel-Troger M, et al.: Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001, 27:686–693. A cell culture assay of neurotoxicity may suggest that a low-molecular weight toxin may play a role in the pathogenesis of critical illness polyneuropathy.PubMedCrossRefGoogle Scholar
  43. 43.
    Bolton CF: Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996, 24:1408–1416.PubMedCrossRefGoogle Scholar
  44. 44.
    Breuer AC: Critical illness polyneuropathy: an outdated concept. Muscle Nerve 1999, 22:422–424.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Shawn J. Bird
    • 1
  • Mark M. Rich
    • 1
  1. 1.Department of NeurologyUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations